Fast-track diagnostics will develop assays for use on Biocartis' Idylla testing platform, which searches for multiple pathogens following a single test, or what's known as syndromic multiplex testing.
Bluebird bio, already making headlines with its promising gene therapy, is expanding its efforts in immuno-oncology, pairing up with Five Prime Therapeutics to develop cell therapies for cancer.
One of the leaders of the CAR-T revolution has now aligned itself in an R&D collaboration with one of the top biotechs to emerge in the hot gene editing field. Juno Therapeutics is tying the knot with Editas on three programs, handing over $47 million in an upfront payment and three years of research support along with up to $690 million in milestones.
Flatiron Health's cloud-based electronic health record for cancer patients will soon be interoperable with Varian Medical Systems' Aria oncology information system under the terms of a strategic alliance between the two companies.
Sanofi is betting on the promise of NeuroVive Pharmaceutical's top prospect, buying the South Korean rights to the biotech's Phase III cardiovascular drug.
China Medical Systems Holding has licensed Greater China rights to develop and commercialize Finland's Faron Pharmaceuticals' Traumakine (FP-1201), a recombinant human interferon (IFN) beta-1a to treat severe and acute respiratory distress syndrome.
Collaboration between biotech companies from the U.S. and China is in a good state of flux as plays from "friends and family" and signs of growing venture capital and big pharma licensing deals are in motion at the same time, according to Andrew Chan, senior vice president of corporate business development for China only Nasdaq-listed biotech, Cellular Biomedicine Group.
Companion Medical, a California startup with a Bluetooth-enabled insulin pen and smartphone app, pulled in Series B financing this week, led by Big Pharma player Eli Lilly. Though the amount was undisclosed, the move marks a step forward for Lilly into the world of drug delivery technology, for which the company is currently building an R&D center in Cambridge, MA.
A heavyweight consortium of Chinese biomedical- and healthcare-focused funds said it would acquire San Diego-based biotech Ambrx, which abandoned an initial public offering last year, in a deal that opens a path to cutting-edge candidates in oncology therapies.
The antibody experts at arGEN-X have teamed up with dermatology-focused biotech Leo Pharma on a treatment for inflammatory skin diseases, inking a deal worth up to $116 million.